ArticleInternational urology and nephrology2026
The prognostic value of hyperhomocysteinemia in IgA nephropathy.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeHyperhomocysteinemia (HHcy) is widely observed in chronic kidney disease (CKD) patients. In early CKD stages, HHcy is more prevalent in IgA nephropathy (IgAN) patients. Here, we investigated the relationship between HHcy and renal outcomes among patients with IgAN.
methodsThis study evaluated patients with IgAN who underwent diagnostic renal biopsies in the National Clinical Research Center of Kidney Diseases Jinling Hospital from October 2012 to June 2024. Patients were stratified into two groups based on serum homocysteine (Hcy) levels: an HHcy group and a normal Hcy group. A comprehensive comparison between groups was conducted, assessing clinical and pathological manifestations. The end point was end-stage kidney disease (ESKD). The impact of HHcy on renal outcomes was evaluated using multivariate Cox proportional hazards regression models and Kaplan-Meier survival analysis.
resultsThis study enrolled 366 patients with biopsy-proven IgAN. The cohort had a median age of 37 years, with 60.4% male, and a median serum Hcy level of 13.6 μmol/L. HHcy was present at diagnosis in 145 patients (39.6%). IgAN patients with HHcy demonstrated significantly worse renal function and histopathological severity compared to those with normal Hcy levels. These manifestations included lower eGFR, higher proteinuria, more severe global glomerulosclerosis and crescent lesions, a higher incidence of T1/T2 lesions, and more severe acute and chronic tubular injury, ultimately culminating in a higher incidence of ESKD (all P < 0.05). After a median follow-up of 42.5 months, 38 patients (10.4%) progressed to end-stage kidney disease (ESKD), 33 of whom were in the HHcy group. On multivariate Cox regression analysis, HHcy was identified as an independent risk factor for ESKD in patients with IgAN (HR = 4.008, 95% CI 1.093-14.691, P = 0.036). Kaplan-Meier survival analysis demonstrated significantly poorer renal survival in the HHcy group (P < 0.001).
conclusionOur findings suggest that hyperhomocysteinemia is associated with worse renal function and more severe renal pathological manifestations, and serves as an independent risk factor for kidney failure in IgAN.
Indexed as
Identifiers
41372607What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.